vs
Side-by-side financial comparison of Guardian Pharmacy Services, Inc. (GRDN) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
Guardian Pharmacy Services, Inc. is the larger business by last-quarter revenue ($336.6M vs $207.8M, roughly 1.6× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 4.0%, a 53.4% gap on every dollar of revenue.
CVS Pharmacy Inc. is an American retail corporation. A subsidiary of CVS Health, it is headquartered in Woonsocket, Rhode Island. Originally named the Consumer Value Stores, it was founded in Lowell, Massachusetts, in 1963.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
GRDN vs IDYA — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $336.6M | $207.8M |
| Net Profit | $13.5M | $119.2M |
| Gross Margin | 22.7% | — |
| Operating Margin | 5.3% | 52.2% |
| Net Margin | 4.0% | 57.4% |
| Revenue YoY | 2.2% | — |
| Net Profit YoY | 46.1% | 330.1% |
| EPS (diluted) | $0.21 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $336.6M | — | ||
| Q4 25 | $397.6M | — | ||
| Q3 25 | $377.4M | $207.8M | ||
| Q2 25 | $344.3M | — | ||
| Q1 25 | $329.3M | — | ||
| Q3 24 | $314.4M | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
| Q1 26 | $13.5M | — | ||
| Q4 25 | $20.9M | — | ||
| Q3 25 | $9.8M | $119.2M | ||
| Q2 25 | $9.0M | — | ||
| Q1 25 | $9.4M | — | ||
| Q3 24 | $-122.0M | $-51.8M | ||
| Q2 24 | — | $-52.8M | ||
| Q1 24 | — | $-39.6M |
| Q1 26 | 22.7% | — | ||
| Q4 25 | 21.5% | — | ||
| Q3 25 | 19.8% | — | ||
| Q2 25 | 19.8% | — | ||
| Q1 25 | 19.5% | — | ||
| Q3 24 | 19.4% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q1 26 | 5.3% | — | ||
| Q4 25 | 7.7% | — | ||
| Q3 25 | 4.3% | 52.2% | ||
| Q2 25 | 3.7% | — | ||
| Q1 25 | 3.9% | — | ||
| Q3 24 | -33.3% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q1 26 | 4.0% | — | ||
| Q4 25 | 5.3% | — | ||
| Q3 25 | 2.6% | 57.4% | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 2.9% | — | ||
| Q3 24 | -38.8% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q1 26 | $0.21 | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $1.33 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $-0.60 | ||
| Q2 24 | — | $-0.68 | ||
| Q1 24 | — | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.9M | $786.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $232.4M | $1.1B |
| Total Assets | $426.9M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $64.9M | — | ||
| Q4 25 | $65.6M | — | ||
| Q3 25 | $36.5M | $786.9M | ||
| Q2 25 | $18.8M | — | ||
| Q1 25 | $14.0M | — | ||
| Q3 24 | $37.2M | $920.0M | ||
| Q2 24 | — | $701.7M | ||
| Q1 24 | — | $698.8M |
| Q1 26 | — | — | ||
| Q4 25 | $0 | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $34.3M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q1 26 | $232.4M | — | ||
| Q4 25 | $217.9M | — | ||
| Q3 25 | $195.5M | $1.1B | ||
| Q2 25 | $179.7M | — | ||
| Q1 25 | $163.2M | — | ||
| Q3 24 | $133.9M | $1.2B | ||
| Q2 24 | — | $931.7M | ||
| Q1 24 | — | $935.3M |
| Q1 26 | $426.9M | — | ||
| Q4 25 | $412.7M | — | ||
| Q3 25 | $390.0M | $1.2B | ||
| Q2 25 | $356.3M | — | ||
| Q1 25 | $334.0M | — | ||
| Q3 24 | $348.0M | $1.2B | ||
| Q2 24 | — | $973.7M | ||
| Q1 24 | — | $961.5M |
| Q1 26 | — | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | 0.26× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.1M | $142.2M |
| Free Cash FlowOCF − Capex | — | $142.2M |
| FCF MarginFCF / Revenue | — | 68.4% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 0.45× | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $6.1M | — | ||
| Q4 25 | $34.6M | — | ||
| Q3 25 | $28.2M | $142.2M | ||
| Q2 25 | $19.9M | — | ||
| Q1 25 | $17.6M | — | ||
| Q3 24 | — | $-49.2M | ||
| Q2 24 | — | $-32.9M | ||
| Q1 24 | — | $-43.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $24.2M | $142.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $-49.7M | ||
| Q2 24 | — | $-33.9M | ||
| Q1 24 | — | $-45.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 6.4% | 68.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.1% | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q1 26 | 0.45× | — | ||
| Q4 25 | 1.65× | — | ||
| Q3 25 | 2.87× | 1.19× | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 1.86× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
